Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ligand Pharmaceuticals has entered into a worldwide license agreement with ABBA Therapeutics AG, a Swiss biotechnology company developing immuno-oncology therapies.
Subscribe to our email newsletter
Under the license, ABBA will be able to use the OmniRat, OmniMouse and OmniFlic platforms to generate fully human mono- and bispecific antibodies.
Ligand is to receive an initial access payment, and will be eligible to receive clinical milestone payments and royalties for each successful OmniAb antibody. ABBA will be responsible for all costs related to the program.
Ligand CEO John Higgins said: "OmniAb will provide ABBA with industry-leading technology for generation of novel antibody therapeutics to further their therapeutic strategy.
"This is the third OmniAb license deal since the close of the OMT acquisition and the 19th overall OmniAb Ligand partner, and continues to show the licensing power that the OmniAb franchise brings to Ligand."
About OmniAb
OmniAb includes three transgenic animal platforms for producing mono- and bispecific human therapeutic antibodies.
OmniRat is the industry’s first human monoclonal antibody technology based on rats. It has a complete immune system with a diverse antibody repertoire and generates antibodies with human idiotypes as effectively as wild-type animals make rat antibodies. OmniMouse is a transgenic mouse that complements OmniRat and expands epitope coverage.
OmniFlic is an engineered rat with a fixed light chain for development of bispecific, fully human antibodies. The three platforms use patented technology, have broad freedom to operate and deliver fully human antibodies with high affinity, specificity, expression, solubility and stability.